Research Focus

Former Employee. Medicine; Clinical Research Supervisor

Recent additions – View all

1. Efficacy and toxicity of therapy immediately after treatment with nivolumab in relapsed multiple myeloma

   Journal Article

   Pianko, M. J.; Funt, S. A.; Page, D. B.; Cattry, D.; Scott, E. C.; Ansell, S. M.; Borrello, I. M.; Gutierrez, M.; Lendvai, N.; Hassoun, H.; more...
   Leukemia and Lymphoma (2018)

   Fulltext@MSK | Save
2. Nivolumab in patients with relapsed or refractory hematologic malignancy: Preliminary results of a phase Ib study

   Journal Article

   Lesokhin, A. M.; Ansell, S. M.; Armand, P.; Scott, E. C.; Halwani, A.; Gutierrez, M.; Millenson, M. M.; Cohen, A. D.; Schuster, S. J.; Lebovic, D.; more...
   Journal of Clinical Oncology (2016)

   Fulltext@MSK | Save
3. The long PD-1 receptor binding kinetics of nivolumab may increase efficacy of subsequent therapy in relapsed and refractory multiple myeloma patients

   Meeting Abstract

   Funt, S. A.; Page, D. B.; Cattry, D.; Lendvai, N.; Hassoun, H.; Landgren, O.; Borrello, I. M.; Lesokhin, A. M.
   Blood (2015)

   Fulltext@MSK | Save